AtriCure Inc. (NASDAQ:ATRC)’s share price dropped 4.7% during mid-day trading on Wednesday . The stock traded as low as $14.96 and last traded at $14.98, with a volume of 74,408 shares changing hands. The stock had previously closed at $15.72.

ATRC has been the topic of several recent analyst reports. Zacks Investment Research lowered AtriCure from a “buy” rating to a “hold” rating in a research note on Tuesday, April 26th. Needham & Company LLC reiterated a “buy” rating on shares of AtriCure in a research note on Saturday, April 30th. TheStreet lowered AtriCure from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. JMP Securities initiated coverage on AtriCure in a research note on Thursday, June 30th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, Canaccord Genuity reiterated a “buy” rating on shares of AtriCure in a research note on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $20.13.

The company has a 50-day moving average of $14.99 and a 200 day moving average of $15.71. The company’s market cap is $480.76 million.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, August 4th. The medical device company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $39.70 million for the quarter, compared to analysts’ expectations of $39.84 million. The company’s revenue was up 21.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.18) EPS. On average, analysts anticipate that AtriCure Inc. will post ($1.16) earnings per share for the current fiscal year.

In other news, Director Elizabeth D. Krell sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $15.20, for a total value of $76,000.00. Following the transaction, the director now owns 15,162 shares of the company’s stock, valued at $230,462.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Several hedge funds and institutional investors have recently added to or reduced their stakes in the company. RS Investment Management Co. LLC boosted its position in AtriCure by 21.1% in the fourth quarter. RS Investment Management Co. LLC now owns 2,679,551 shares of the medical device company’s stock valued at $60,129,000 after buying an additional 466,200 shares during the last quarter. Victory Capital Management Inc. boosted its position in AtriCure by 15.3% in the fourth quarter. Victory Capital Management Inc. now owns 51,647 shares of the medical device company’s stock valued at $1,159,000 after buying an additional 6,845 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in AtriCure by 20.2% in the fourth quarter. Wells Fargo & Company MN now owns 659,070 shares of the medical device company’s stock valued at $14,789,000 after buying an additional 110,890 shares during the last quarter.

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.